Doctors Without Borders (MSF) has called for equitable, non-discriminatory access to three candidate treatments—MBP134, remdesivir, and obeldesivir—currently being tested in clinical trials for Ebola caused by the Bundibugyo virus in the Democratic Republic of the Congo. The organization emphasizes that public funds and philanthropic contributions support these developments.
In Plain English: The Clinical Takeaway
- Candidate Treatments: MBP134, remdesivir, and obeldesivir are experimental medications currently undergoing evaluation in the “PARTNERS” and “EBO-PEP” clinical trials.
- The Access Barrier: Publicly available information regarding pricing, supply capacity, and licensing agreements remains very limited, raising concerns about future treatment availability.
- Public Health Strategy: Medical organizations are pushing pharmaceutical developers and policymakers to integrate transparent access plans and strategic reserves now, rather than relying on reactive donations during an outbreak.
The Status of Bundibugyo Virus Clinical Trials
The Democratic Republic of the Congo is currently hosting the “PARTNERS” and “EBO-PEP” clinical trials, which evaluate the efficacy and safety of MBP134, remdesivir, and obeldesivir. Developed by Mapp Biopharmaceutical and Gilead Sciences, these candidate therapies represent a scientific window of opportunity against the Bundibugyo strain of the Ebola virus.
However, Mónica Rull, Deputy Executive Director of MSF Access, notes that scientific progress alone does not guarantee equitable patient outcomes. Past public health emergencies demonstrated that successful clinical results can still be followed by delays, limited supplies, and a reliance on one-time charitable donations that restrict rapid deployment.
Addressing Transparency and Supply Gaps
Despite repeated requests from public health advocates, information concerning future supply capacity, pricing structures, and intellectual property licensing remains limited. Transparency from the earliest phases of clinical evaluation is critical to prevent commercial decisions from dictating who receives life-saving interventions.
Public health strategies must also account for pediatric populations. Ensuring that treatments designed for children are explicitly integrated into early development and access roadmaps remains a core demand from humanitarian organizations monitoring the trials.
| Candidate Treatment | Developer | Active Trials |
|---|---|---|
| MBP134 | Mapp Biopharmaceutical | PARTNERS / EBO-PEP |
| Remdesivir | Gilead Sciences | PARTNERS / EBO-PEP |
| Obeldesivir | Gilead Sciences | PARTNERS / EBO-PEP |
Contraindications & When to Consult a Doctor
As these therapeutic candidates remain within active clinical trials, they are not currently available for routine clinical use outside of trial protocols.
Outlook on Global Health Policy
The call for transparency serves as a blueprint for pharmaceutical companies, health policy makers, funders, and United Nations agencies. Integrating enforceable access conditions directly into clinical trial agreements ensures that successful innovations translate into accessible public health tools for the communities most vulnerable to outbreaks.
References
- Doctors Without Borders (MSF). Report on candidate treatments against Ebola Bundibugyo. Released September 2024.
